These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32802081)

  • 1. Medications for Hypertension Change the Secretome Profile from Marrow Stromal Cells and Peripheral Blood Monocytes.
    Satani N; Giridhar K; Cai C; Wewior N; Norris DD; Aronowski J; Savitz SI
    Stem Cells Int; 2020; 2020():8894168. PubMed ID: 32802081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes
    Satani N; Zhang X; Giridhar K; Wewior N; Cai C; Aronowski J; Savitz SI
    Front Pharmacol; 2021; 12():589418. PubMed ID: 33959001
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes.
    Satani N; Giridhar K; Cai C; Wewior N; Norris DD; Olson SD; Aronowski J; Savitz SI
    Brain Res; 2019 Oct; 1720():146298. PubMed ID: 31220426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood monocytes as a therapeutic target for marrow stromal cells in stroke patients.
    Satani N; Parsha K; Davis C; Gee A; Olson SD; Aronowski J; Savitz SI
    Front Neurol; 2022; 13():958579. PubMed ID: 36277912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia Pre-Conditioned Embryonic Mesenchymal Stem Cell Secretome Reduces IL-10 Production by Peripheral Blood Mononuclear Cells.
    Lotfinia M; Lak S; Mohammadi Ghahhari N; Johari B; Maghsood F; Parsania S; Sadegh Tabrizi B; Kadivar M
    Iran Biomed J; 2017 Jan; 21(1):24-31. PubMed ID: 27132108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
    Nemati F; Rahbar-Roshandel N; Hosseini F; Mahmoudian M; Shafiei M
    Clin Exp Hypertens; 2011; 33(2):66-76. PubMed ID: 21309738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants.
    Parsha K; Mir O; Satani N; Yang B; Guerrero W; Mei Z; Cai C; Chen PR; Gee A; Hanley PJ; Aronowski J; Savitz SI
    Cytotherapy; 2017 Jan; 19(1):36-46. PubMed ID: 27856228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming.
    Redondo-Castro E; Cunningham CJ; Miller J; Brown H; Allan SM; Pinteaux E
    Stem Cell Res Ther; 2018 Jan; 9(1):11. PubMed ID: 29343288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
    Sepehri Z; Masoumi M; Ebrahimi N; Kiani Z; Nasiri AA; Kohan F; Sheikh Fathollahi M; Kazemi Arababadi M; Asadikaram G
    PLoS One; 2016; 11(12):e0168312. PubMed ID: 28033321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
    Roberts DH; Tsao Y; Grimmer SF; Winstanley PA; Orme ML; Breckenridge AM
    Br J Clin Pharmacol; 1987 Aug; 24(2):163-72. PubMed ID: 2887190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
    J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro.
    Redondo-Castro E; Cunningham C; Miller J; Martuscelli L; Aoulad-Ali S; Rothwell NJ; Kielty CM; Allan SM; Pinteaux E
    Stem Cell Res Ther; 2017 Apr; 8(1):79. PubMed ID: 28412968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
    Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
    Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs.
    Brody R; Peleg E; Grossman E; Sharabi Y
    Am J Hypertens; 2009 Oct; 22(10):1126-9. PubMed ID: 19730415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats.
    Ramos-Filho AC; Moscoso JA; Calmasini F; Faria Jde A; Anhê GF; Mónica FZ; Antunes E
    Eur J Pharmacol; 2014 Sep; 738():285-92. PubMed ID: 24881522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.
    Cassano JM; Schnabel LV; Goodale MB; Fortier LA
    Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.